natgillin/translations-raw huggingface dataset:
Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid arthritis (RA) patients the mean steady-state trough concentrations were approximately 5 g/ml (without concomitant methotrexate) and 8 to 9 g/ml (with concomitant methotrexate), respectively.
Nakon supkutane primjene adalimumaba u dozi od 40 mg svaka dva tjedna u odraslih bolesnika s reumatoidnim artritisom srednje vrijednosti najniže koncentracije lijeka u stanju dinamičke ravnoteže bile su približno 5 μg /ml (bez istodobne primjene metotreksata), odnosno 8 do 9 μg/ml (uz metotreksat).
Following subcutaneous administration of a single 75 mg/m2 dose, azacitidine was rapidly absorbed with peak plasma concentrations of 750 ± 403 ng/mL occurring at 0.5 h after dosing (the first sampling point).
Nakon supkutane primjene jednokratne doze od 75 mg/m2, azacitidin se brzo apsorbirao te se vršna koncentracija azacitidina u plazmi od 750 ± 403 ng/mL postigla za 0,5 h nakon primjene (prva točka uzorkovanja).
Following subcutaneous administration of a single 75 mg/m2 dose, mean exposure values (AUC and Cmax) from subjects with mild, moderate and severe renal impairment were increased by 11-21%, 15-27%, and 41-66%, respectively, compared to normal renal function subjects.
U usporedbi s ispitanicima s normalnom funkcijom bubrega, nakon supkutane primjene jednokratne doze od 75 mg/m2, srednje vrijednosti izloženosti (AUC i Cmax) bile su povišene u ispitanika s blagim oštećenjem bubrega za 11-21 %, u onih s umjerenim oštećenjem za 15-27 %, a u bolesnika s teškim oštećenjem bubrega za 41-66 %.
Following subcutaneous administration of HyQvia, peak serum IgG levels are achieved in the recipient’s circulation after approximately 3 to 5 days.
Nakon supkutane primjene lijeka HyQvia najviše koncentracije IgG-a u serumu dostignute su u cirkulaciji primatelja nakon približno 3 do 5 dana.
Following subcutaneous administration of mepolizumab the mean terminal half-life (t1/2) ranged from 16 to 22 days.
Nakon supkutane primjene mepolizumaba, srednji terminalni poluvijek (t1/2) kretao se između 16 i 22 dana.
Following subcutaneous administration of peginterferon beta-1a in multiple sclerosis patients, the peak concentration was reached between 1 to 1.5 days post-dose.
Nakon supkutane primjene peginterferona beta-1a u bolesnika s multiplom sklerozom, vršna koncentracija je postignuta između 1 do 1,5 dana nakon primjene doze.
Following subcutaneous administration of recommended doses , serum concentrations were maintained above 10ng/ml for 8 to 16 hours.
Nakon supkutane primjene preporučenih doza serumske koncentracije su se održale iznad 10 ng/ml od 8 do 16 sati.
Following subcutaneous administration of recommended doses , serum concentrations were maintained above 10ng/ml for 8 to 16 hours.
Nakon supkutane primjene preporučenih doza, serumske koncentracije su se održale iznad 10 ng/ml od 8 do 16 sati.
Following subcutaneous administration of recommended doses, serum concentrations were maintained above10 ng/ml for 8 - 16 hours.
Nakon supkutane primjene preporučenih doza, koncentracije u serumu bile su održane iznad 10 ng/ml tijekom 8-16 sati.
Following subcutaneous administration of the implant, most of the active substance is released within the first 48 hours with over 90% released by Day 5.
Nakon supkutane primjene implantata, većina djelatne tvari se otpušta unutar prvih 48 sati, a do 5. dana se otpusti više od 90% tvari.
Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2 h.
Nakon supkutane primjene u bolesnika sa šećernom bolešću tipa 2, medijan vršne koncentracije eksenatida u plazmi postiže se za 2 sata.
Following subcutaneous administration, choriogonadotropin alfa is eliminated from the body with a terminal halflife of about 30 hours, and the absolute bioavailability is about 40%.
Nakon potkožne primjene koriogonadotropin alfa eliminira se iz tijela uz konačno vrijeme poluraspada od oko 30 sati, a potpuna bioraspoloživost je oko 40%.
Following subcutaneous administration, choriogonadotropin alfa is eliminated from the body with a terminal halflife of about 30 hours, and the absolute bioavailability is about 40%.
Nakon potkožne primjene koriogonadotropin alfa eliminira se iz tijela uz terminalni poluvijek od oko 30 sati, a potpuna bioraspoloživost je oko 40%.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 μg/ml in dogs and 1.1 μg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively.
Po subkutanom davanju meloksikam je u cjelosti bioraspoloživ te prosječno kod pasa za približno 2.5 sata postiže vršnu koncentraciju u plazmi od 0.73 μg/ml, dok kod mačaka za približno 1.5 sat postiže vršnu koncentraciju od 1.1 μg/ml.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 1.1 µg/ml were reached approximately 1.5 hours post administration.
Nakon supkutane primjene, meloksikam je potpuno bioraspoloživ, a maksimalne prosječne koncentracije u plazmi od 1,1 µg/ml postignute su približno 1,5 sat poslije primjene.
Following subcutaneous administration, peak plasma concentrations of certolizumab pegol were attained between 54 and 171 hours post-injection.
Nakon supkutane primjene vršne koncentracije certolizumabpegola u plazmi postižu se između 54 i 171 sati nakon injiciranja.
Following subcutaneous administration, the absolute bioavailability is about 70 %.
Nakon potkožne primjene, apsolutna bioraspoloživost je oko 70%.
Following subcutaneous administration, the absolute bioavailability is approximately 60 %.
Nakon supkutane primjene, apsolutna bioraspoloživost iznosi približno 60%.
Following subcutaneous administration, the protracted action profile is based on three mechanisms: self-association, which results in slow absorption; binding to albumin; and higher enzymatic stability towards the dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP) enzymes, resulting in a long plasma half-life.
Nakon supkutane primjene, profil produljenog djelovanja zasniva se na tri mehanizma: samoudruživanje, što dovodi do polagane apsorpcije; vezanje za albumin i viša enzimatska stabilnost prema enzimima dipeptidil peptidazi-4 (DPP-IV) i neutralnoj endopeptidazi (NEP), što rezultira dugim poluvijekom u plazmi.
Following subcutaneous administration, the protracted action profile is based on three mechanisms: self­association, which results in slow absorption; binding to albumin; and higher enzymatic stability towards the dipeptidyl peptidase ­4 (DPP­4) and neutral endopeptidase (NEP) enzymes, resulting in a long plasma half­life.
Nakon supkutane primjene, profil produljenog djelovanja zasniva se na tri mehanizma: samoudruživanje, što dovodi do polagane apsorpcije; vezanje za albumin i viša enzimatska stabilnost prema enzimima dipeptidil peptidazi-4 (DPP-4) i neutralnoj endopeptidazi (NEP), što rezultira dugim poluvijekom u plazmi.
Following subcutaneous dosing in patients with asthma, mepolizumab exhibited approximately dose- proportional pharmacokinetics over a dose range of 12.5 mg to 250 mg.
Nakon supkutane primjene u bolesnika s astmom, mepolizumab je pokazao farmakokinetiku približno proporcionalnu dozi u rasponu doza od 12,5 mg do 250 mg.
Following subcutaneous dosing in RA patients, the time to peak serum tocilizumab concentrations tmax was 2.8 days.
Vrijeme do postizanja vršnih koncentracija tocilizumaba u serumu (tmax) nakon supkutane primjene u bolesnika s RA iznosilo je 2,8 dana.
Following surgery all patients received 3 cycles of 5- fluorouracil (600 mg/m2), epirubicin (90 mg/m2), cyclophosphamide (600 mg/m2) (FEC) given intravenously every three weeks, and trastuzumab administered intravenously every three weeks to complete one year of therapy.
Nakon kirurškog zahvata, sve su bolesnice primile 3 ciklusa 5-fluorouracila (600 mg/m2), epirubicina (90 mg/m2) i ciklofosfamida (600 mg/m2) (FEC), koji su se primjenjivali intravenski svaka tri tjedna, kao i trastuzumab primijenjen intravenski svaka tri tjedna do završetka 1-godišnjeg razdoblja liječenja.
following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1).
nakon kirurškog zahvata, kemoterapije (neoadjuvantne ili adjuvantne) i radioterapije (ako su provedeni) (vidjeti dio 5.1).
Following surgery, patients should be treated with adjuvant trastuzumab to complete 1 year of treatment (see section 5.1).
Nakon kirurškog zahvata, bolesnike treba adjuvantno liječiti trastuzumabom do završetka 1-godišnjeg razdoblja liječenja (vidjeti dio 5.1).
Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.
Nakon prestanka liječenja filgrastimom, broj cirkulirajućih neutrofila smanji se za 50% u roku od 1 do 2 dana te na normaln e vrijednosti unutar 1 do 7 dana.
Following the administration of 24 mg/m2 (up to a maximum of 40 mg) subcutaneously every other week to patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17 years the mean trough steady-state (values measured from Week 20 to 48) serum adalimumab concentration was 5.6
Nakon primjene 24 mg/m2 (do maksimalno 40 mg) supkutano svaki drugi tjedan u bolesnika s poliartikularnim juvenilnim idiopatskim artritisom (JIA) u dobi od 4 do 17 godina, srednja vrijednost najniže koncentracije adalimumaba u serumu u stanju dinamičke ravnoteže (vrijednosti mjerene od
Following the administration of a 100 mg/m2 dose given as a one hour infusion a mean peak plasma level of 3.7 μg/ml was obtained with a corresponding AUC of 4.6 h.μg/ml.
Nakon primjene doze od 100 mg/m2 putem jednosatne infuzije, dobivena je srednja vrijednost vršne koncentracije lijeka u plazmi od 3,7 μg/ml s odgovarajućim AUC-om od 4,6 h μg/ml.
Following the administration of a 100 mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 µg/ml was obtained with a corresponding AUC of 4.6 h.µg/ml.
Nakon primjene doze od 100 mg/ m2 putem jednosatne infuzije, dobivena je srednja vrijednost vršne razine lijeka u plazmi od 3,7 μg/ml s odgovarajućim AUC-om od 4,6 h μg/ml.
Following the administration of a 100 mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 µg/ml was obtained with a corresponding AUC of 4.6 h.µg/ml.
Nakon primjene doze od 100 mg/m2 putem jednosatne infuzije, dobivena je srednja vrijednost vršne koncentracije lijeka u plazmi od 3,7 μg/ml s odgovarajućim AUC-om od 4,6 h μg/ml.
Following the administration of a 30 micrograms/kg bolus followed by a 4 micrograms/kg/min infusion (the PCI dose), platelet inhibition is observed within two minutes.
Nakon primjene bolusa od 30 mikrograma/kg iza kojeg slijedi infuzija od 4 mikrograma/kg/min (PCI doza), inhibicija trombocita opažena je unutar dvije minute.
Following the administration of a 4-fold overdose of vaccine no adverse reactions other than those described under section “Adverse reactions” have been observed.
Nakon predoziranja četverostrukom dozom cjepiva nisu primijećene druge nuspojave osim onih opisanih u dijelu Nuspojave.
Following the administration of a double dose of vaccine no adverse reactions other than those described in section 4.6 have been observed.
Nakon primjene dvostruke doze cjepiva nisu primijećene nuspojave osim obih opisanih u odjeljku 4.6.
Following the administration of a double dose of vaccine no adverse reactions other than those described in section 6 have been observed.
Nakon primjene dvostruke doze cjepiva nisu primijećene nuspojave različite od onih opisanih u odjeljku 6.
Following the administration of a double dose of vaccine no side effects other than those described in section 4.6 have been observed.
Primjena duple doze cjepiva, nema nikakvih drugih učinaka osim onih koji su opisani u poglavlju 4.6.
Following the administration of a double dose of vaccine no side effects other than those described under “adverse reactions” have been observed.
Primjenom duple doze cjepiva, nisu primijećene nuspojave osim onih opisanih pod „nuspojave“.
Following the administration of a double dose of vaccine, no side-effects other than those described under section 4.6 have been observed.
Nakon primjene duple doze cjepiva osim onih nuspojava navedenih u poglavlju 4.6, nisu primjećene druge nuspojave.
Following the administration of a double dose, no adverse reactions other than those described in section 4.6 have been observed.
Nakon primjene dvostruke doze nisu primijećene dodatne reakcije osim onih opisanih u odjeljku 4.6.
Following the administration of a single 50 mg dose, the AUC0- of eltrombopag was 41% higher in subjects with mild hepatic impairment and 80% to 93% higher in subjects with moderate to severe hepatic impairment compared with healthy volunteers.
Nakon jednokratne primjene doze od 50 mg, AUC0- eltrombopaga je bila 41% viša u ispitanika s blagim oštećenjem jetre, i 80% do 93% viša u ispitanika s umjerenim do teškim oštećenjem jetre, u odnosu na zdrave dobrovoljce.
Following the administration of multiple doses, daptomycin AUC0-tau were 387, 438, 439 and 466 µg×hr/ml for 12-17 years, 7-11 years, 2-6 years and 1-<2 years, respectively, indicating that the daptomycin exposure was similar across the different age groups after dose adjustment based on body weight and age.
Nakon primjene višestrukih doza, AUC0-tau daptomicina bila je 387 µg×sat/ml u skupini 12-17 godina, 438 µg×sat/ml u skupini 7-11 godina, 439 µg×sat/ml u skupini 2-6 godina i 466 µg×sat/ml u skupini 1-<2 godina, što ukazuje na sličnu izloženost daptomicinu unutar različitih dobnih skupina nakon što je doza prilagođena tjelesnoj težini i dobi.
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4 ng/ml.
Nakon primjene Kentere, koncentracija oksibutinina u plazmi povećava se tijekom približno 24 do 48 sati i dostiže prosječnu maksimalnu koncentraciju od 3 do 4 ng/ml.
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 7 days, reaching average maximum concentrations of 4 to 5 ng/ml.
Nakon primjene Kentere, koncentracija oksibutinina u plazmi povećava se približno 7 dana i dostiže prosječnu maksimalnu koncentraciju od 4 do 5 ng/ml.
Following the assessment of the integrated safety data from the clinical trial database, the PRAC agreed with the changes proposed.
Nakon ocjene objedinjenih podataka o sigurnosti primjene lijeka iz baze podataka kliničkih ispitivanja, PRAC se složio s predloženim izmjenama.
Following the booster dose, antibody concentrations increased from the pre-booster level for all 13 serotypes.
Nakon docjepljivanja („booster“) povećale su se koncentracije protutijela na svih 13 serotipova u odnosu na koncentracije prije docjepljivanja.
Following the dose regimen of 8 mg/kg every 2 weeks, the geometric means of ramucirumab Cmin were 49.5 μg/ml (range of 6.3-228 μg/ml) and 74.4 μg/ml (range of 13.8-234 μg/ml) prior to administration of the fourth and seventh dose, respectively of ramucirumab given as a single agent, in serum from patients with advanced gastric cancer.
Nakon režima doziranja od 8 mg/kg svaka 2 tjedna, geometrijska srednja vrijednost Cmin ramucirumaba u serumu bolesnika s uznapredovalim rakom želuca iznosila je 49,5 μg/ml (raspon: 6,3-228 μg/ml) prije primjene četvrte doze te 74,4 μg/ml (raspon: 13,8-234 μg/ml) prije primjene sedme doze ramucirumaba u monoterapiji.
Following the dose regimen of 8 mg/kg ramucirumab every 2 weeks in combination with FOLFIRI, the geometric means of ramucirumab Cmin were 46.3 μg/ml (range of 7.7-119 μg/ml) and 65.1 μg/ml (range of 14.5-205 μg/ml) prior to administration of the third and fifth dose, respectively, in serum from patients with mCRC.
Nakon režima primjene ramucirumaba u dozi od 8 mg/kg svaka 2 tjedna u kombinaciji s protokolom FOLFIRI, geometrijska srednja vrijednost Cmin ramucirumaba u serumu bolesnika s metastatskim kolorektalnim rakom iznosila je 46,3 μg/ml (raspon: 7,7-119 μg/ml) prije primjene treće doze te 65,1 μg/ml (raspon: 14,5-205 μg/ml) prije primjene pete doze ramucirumaba.
Following the dose regimen of 800 mg necitumumab on day 1 and day 8 of a 21 day schedule, the geometric mean of necitumumab Cmin was 98.5 μg/mL (Coefficient of Variation 80 %) in serum from patients with squamous NSCLC after five cycles of treatment in combination with gemcitabine and cisplatin.
Nakon režima primjene necitumumaba u dozi od 800 mg 1. i 8. dana 21-dnevnog rasporeda, geometrijska srednja vrijednost Cmin necitumumaba u serumu bolesnika s planocelularnim NSCLC-om nakon pet ciklusa liječenja u kombinaciji s gemcitabinom i cisplatinom iznosila je 98,5 μg/ml (koeficijent varijacije [CV]: 80%).
Following the dose titration period, the child’s sialorrhoea should be monitored, in conjunction with the carer at no longer than 3 monthly intervals, to assess changes in efficacy and/or tolerability over time, and the dose adjusted accordingly.
Nakon razdoblja titracije potrebno je pratiti djetetovu sijaloreju, zajedno s njegovateljem i u razmacima od najviše 3 mjeseca, kako bi se ocijenile promjene djelotvornosti i/ili podnošljivosti tijekom vremena i po potrebi provela prilagodba doze.
Following the end of the INCIVO treatment, please see the ribavirin package leaflet regarding continued contraception requirements.
Kada završite liječenje INCIVOM, molimo vas pročitajte što piše u uputi o lijeku za ribavirin o potrebama daljnjeg sprječavanja trudnoće.
Following the finger extension procedure(s) and fitting patient with a splint (with treated joint in maximum extension), patients should be instructed to:
Nakon postupka ekstenzije prsta i davanja udlage (tako da liječeni zglob bude u maksimalnoj ekstenziji), bolesnicima treba savjetovati sljedeće:
Following the first administration, it is advised that the patient be kept under medical supervision for 30 minutes to ensure there is no allergic/pseudo-allergic reaction to the injection.
Nakon prve primjene, uputno je pacijenticu zadržati pod liječničkim nadzorom 30 minuta kako bi bili sigurni da nema pseudoalergijskih reakcija na injekciju lijeka.
Following the first and second infusion, if the patient does not experience a severe adverse drug reaction (ADR), pre-medication with a corticosteroid for subsequent infusions may either be reduced or omitted, at the discretion of the physician.
Ako bolesnik nakon prve i druge infuzije ne razvije tešku nuspojavu na lijek, premedikacija kortikosteroidom se u sljedećim infuzijama može ili primijeniti u manjoj dozi ili izostaviti, sukladno liječničkoj procjeni.
Following the first dose of tenofovir disoproxil fumarate in fed patients, the median Cmax in serum ranged from 213 to 375 ng/ml.
Nakon prve doze tenofovirdizoproksilfumarata primijenjene nahranjenim pacijentima, medijan Cmax u serumu kretao se u rasponu od 213 do 375 ng/ml.
Following the initial administration, ORENCIA should be given 2 and 4 weeks after the first infusion, then every 4 weeks thereafter.
Nakon početne primjene, ORENCIA se treba primijeniti 2 i 4 tjedna nakon prve infuzije te svaka 4 tjedna nakon toga.
Following the initiation of your treatment with this medicine, frequent blood tests will be taken by your doctor to define the correct dose.
U početku liječenja ovim lijekom, bit će potrebne redovite krvne pretrage koje će tražiti Vaš liječnik, kako bi se odredla ispravna doza.
Following the intravenous administration of a 2 micrograms/kg/min infusion of [3H] cangrelor to healthy male volunteers, 93% of total radioactivity was recovered.
Nakon intravenske primjene mikrograma/kg/min infuzije [3H] kangrelora u zdravih muških dobrovoljaca, pronađeno je 93% od ukupne radioaktivnosti.
Following the intravitreal injection, patients should be monitored for any side effects such as (but not limited to) intraocular inflammation/infection and elevation in IOP.
Nakon intravitrealne injekcije bolesnike treba pratiti radi mogućih nuspojava, uključujući (ali ne ograničeno na) intraokularnu upalu/infekciju i povišeni IOT.
Following the introduction of Prevenar and subsequently Prevenar 13 there was a decline in incidence from 2.1 to 0.1 cases per 1000 children (95%) for the Prevenar serotypes plus serotype 6A and a decline in incidence from 0.9 to 0.1 cases per 1000 children (89%) for the additional serotypes 1, 3, 5, 7F, and 19A in Prevenar 13.
Nakon uvođenja Prevenara i potom Prevenara 13 došlo je do smanjenja pojavnosti od 2,1 do 0,1 slučajeva na 1000 ispitivane djece (95%) za serotipove Prevenara i serotip 6A te smanjenja pojavnosti od 0,9 do 0,1 slučajeva na 1000 djece (89%) za dodatne serotipove 1, 3, 5, 7F i 19A u Prevenaru 13.
Following the maximum recommended injection site volume of 10 ml, injection site swellings may be associated with pain on palpation for about one day in individual animals.
Nakon maksimalno preporučenog volumena injekcije od 10 ml, otekline na mjestu injiciranja, u pojedinih životinja, mogu biti bolne na opip jedan dan.
Following the reprocessing of cases using a new methodology as requested in the recent pharmacovigilance inspection, 9 events of ‘rash’ which occurred in 2 patients were identified in the safety database.
Nakon ponovne obrade slučajeva koristeći novu metodologiju prema zahtjevu nedavne farmakovigilancijske inspekcije, 9 slučajeva "osipa" koji se pojavio u 2 bolesnika bili su identificirani u bazi podataka sigurnosti primjene lijeka.
Following the review of the signal assessment report (SSAR), the Innovator MAH confirmed the possible association between levetiracetam and acute kidney injury.
Nakon pregleda izvješća o ocjeni signala (SSAR) nositelj odobrenja inovativnog lijeka potvrdio je moguću povezanost između levetiracetama i akutnog oštećenja bubrega.
Following the second infusion, the dose of intravenous corticosteroid may be reduced (methylprednisolone 60 mg) at the discretion of the physician.
Nakon druge infuzije, liječnik može odlučiti smanjiti dozu intravenskog kortikosteroida (60 mg metilprednizolona).
Following the single dose administration at the recommended dose regimen (11 mg/kg given once every 3 weeks), the clearance was 3.54 ± 0.44 mL/kg/day and half-life was 16.3 ± 4.2 days.
Nakon primjene jedne doze pri preporučenom režimu doziranja (11 mg/kg primijenjeno jedanput svaka 3 tjedna), klirens je bio 3,54 ± 0,44 ml/kg/dan i poluvrijeme je bilo 16,3 ± 4,2 dana.
Following the start of daratumumab treatment, none of the patients tested positive for anti-daratumumab antibodies.
Nakon početka liječenja daratumumabom, nijedan bolesnik nije bio pozitivan na protutijela na daratumumab.
Following the surgery, the patient should receive antibiotics and an appropriate anti- inflammatory medicine.
Nakon kirurškog zahvata, bolesnik treba primiti antibiotike i odgovarajući protuupalni lijek.
Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicyluric acid, 10% phenolic- and 5% acyl- glucuronides of salicylic acid.
Nakon terapijskih doza, otprilike 10% se izluči urinom u obliku salicilatne kiseline, 75% u obliku salicilurične kiseline, 10% u obliku fenolnih i 5% u obliku acil glukuronida salicilatne kiseline.
Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie’s disease are reduced.
Nakon razgradnje plaka smanjena je deformirajuća zakrivljenost penisa i bolesnikove tegobe uzrokovane Peyronijevom bolešću.
Following this dose conversion, 91 study patients (mean age: 64.1 years; 75% male patients) were randomized to receive Numient followed by pre- study LCE or vice versa.
Nakon ove konverzije doze randomiziran je 91 bolesnik iz ispitivanja (srednja vrijednost dobi je 64,1 godina; 75 % bolesnika muškog spola) za primanje Numienta kojem je uslijedilo primanje LCE prije ispitivanja ili obrnuto.
Following this period, the recommended daily dose should be continued (see section 4.5).
Poslije tog perioda treba nastaviti s preporučenom dnevnom dozom (vidjeti dio 4.5).
Following this period, the recommended daily dose should be continued.
Poslije tog perioda treba nastaviti s preporučenom dnevnom dozom.